Healthtech Startups
17,195 companies tagged Healthtech, with their investors and founders.
0 investors
Bluejay Diagnostics develops the Symphony Suite, a near-patient diagnostic testing system that delivers medical test results in about 20 minutes, faster than traditional clinical chemistry labs. The products target healthcare settings inside and outside the lab to reduce wait times and support faster clinical decisions.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Bond Biosciences is a clinical-stage biopharmaceutical company developing non-absorbed oral therapeutics that bind excess ions in the gastrointestinal tract to treat ion-related diseases. Its lead candidate, BBI-001, is designed to inhibit dietary iron absorption for patients with iron overload from Hereditary Hemochromatosis.
0 investors
0 investors
0 investors
0 investors
0 investors
bQuest connects financial advisors with a vetted network of aging care, end-of-life, and after-loss specialists to help clients and families navigate care crises. The platform uses AI-powered guidance to support wealth management firms in serving aging populations.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
BrainsWay develops Deep TMS (Transcranial Magnetic Stimulation) systems for treating psychiatric and neurological conditions including depression, OCD, and smoking addiction. The platform includes brain-targeting stimulators with patented H-Coils, patient management capabilities, and clinical research-grade variants for healthcare providers.
0 investors
BrainXell is a company focused on advancing research and improving patient outcomes through scientific work and services. Its stated mission centers on neuroscience-related research, associated with Dr. Su-Chun Zhang.
0 investors
Branch Therapeutics develops first-in-class, orally available dual-kinase inhibitors designed to modulate WNT/Ξ²-catenin and PI3KΞ± signaling to target cancer stem cells and treatment resistance in solid tumors. The company pairs its therapies with a precision biomarker strategy aimed at safer, longer-lasting responses to cancer treatment.
0 investors
0 investors
0 investors